Complete Story
Announcing a New First-Line Indication for a Genentech Therapy
Genentech is excited to share the news of a new FDA-approved indication. TECENTRIQ® (atezolizumab), in
combination with Avastin® (bevacizumab), paclitaxel, and carboplatin, is now indicated for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer (nsqNSCLC) with no EGFR or ALK genomic tumor aberrations.
Click here to learn more.
